In addition to confirming the involvement of NF-κB activation in contributing to lapatinib resistance in HER2-positive breast cancer cells (Figure 5A), our data also showed that treatment with lapatinib elevates NF-κB activity in TNBC cell lines (Figure 1), uncovering the off-target effect of lapatinib on NF-κB activation. The gene discussed is ERBB2; the disease is breast cancer.